Felicia Ceban
Research collaborator in psychiatry and psychopharmacology
Data updated
Papers
Trials
Research Footprint
Felicia Ceban appears in 5 tracked papers (2022–2023), most studied alongside Ketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Safety & Risk Management.
Most-cited paper: Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis (169 citations).
Frequent co-authors: Jonathan Rosenblat, Joseph Vincenzo and Shokouh Meshkat.
Background & Research
Felicia Ceban is a Canadian mental health researcher and coauthor on multiple systematic reviews and meta-analyses in mood disorders and ketamine psychiatry. Her publications place her within the University Health Network / University of Toronto research ecosystem, with work spanning ketamine efficacy, safety, pharmacogenomics, and related psychiatric topics.
Key Impact
She is a recurring author on ketamine and psychedelic-related psychiatric reviews, contributing to evidence syntheses on treatment-resistant depression, adverse effects, and hallucinogen persisting perceptual disorder.
Collaboration Network
14 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Felicia Ceban is associated with.
University Health Network, Toronto
Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.
View stakeholder →Brain and Cognition Discovery Foundation
Non-ProfitCanada-based foundation backing translational and clinical research programs in mental health, including psychedelic-relevant workstreams.
View stakeholder →University of Toronto
University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.
View stakeholder →